These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 833338)

  • 1. Pharmacokinetics of orally administered hydroflumethiazide in man.
    Yakatan GJ; Smith RB; Frome EL; Doluisio JT
    J Clin Pharmacol; 1977 Jan; 17(1):37-47. PubMed ID: 833338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absorption kinetics of hydroflumethiazide.
    McNamara PJ; Colburn WA; Gibaldi M
    J Clin Pharmacol; 1978 Apr; 18(4):190-3. PubMed ID: 632365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distribution of elimination of hydroflumethiazide in man.
    Brørs O; Jacobsen S
    Eur J Clin Pharmacol; 1979 Sep; 16(2):125-31. PubMed ID: 499309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of hydroflumethiazide during repeated oral administration to healthy subjects.
    Brørs O; Jacobsen S
    Eur J Clin Pharmacol; 1979 May; 15(4):281-6. PubMed ID: 477713
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics of hydroflumethiazide during repeated administration in congestive heart failure.
    Brørs O
    Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):177-81. PubMed ID: 7136723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorometric determination of hydroflumethiazide in human plasma and urine after its oral administration.
    Brors O; Jacobsen S; Arnesen E
    Eur J Clin Pharmacol; 1977 Jan; 11(2):149-54. PubMed ID: 837968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.
    Patel IH; Levy RH; Bauer TG
    Epilepsia; 1975 Dec; 16(5):705-16. PubMed ID: 816644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of a single intravenous and oral dose of pafenolol--a beta 1-adrenoceptor antagonist with atypical absorption and disposition properties--in man.
    Regårdh CG; Lundborg P; Gabrielsson M; Heggelund A; Kylberg-Hanssen K
    Pharm Res; 1990 Dec; 7(12):1222-7. PubMed ID: 1982773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition kinetics of ethambutol in man.
    Lee CS; Brater DC; Gambertoglio JG; Benet LZ
    J Pharmacokinet Biopharm; 1980 Aug; 8(4):335-46. PubMed ID: 7431225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females.
    Cheng H; Leff JA; Amin R; Gertz BJ; De Smet M; Noonan N; Rogers JD; Malbecq W; Meisner D; Somers G
    Pharm Res; 1996 Mar; 13(3):445-8. PubMed ID: 8692739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.
    Guentert TW; Holford NH; Coates PE; Upton RA; Riegelman S
    J Pharmacokinet Biopharm; 1979 Aug; 7(4):315-30. PubMed ID: 512840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haloperidol kinetics after oral and intravenous doses.
    Holley FO; Magliozzi JR; Stanski DR; Lombrozo L; Hollister LE
    Clin Pharmacol Ther; 1983 Apr; 33(4):477-84. PubMed ID: 6831826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans.
    Bressolle F; Brès J; Fauré-Jeantis A
    J Pharm Sci; 1992 Jan; 81(1):26-32. PubMed ID: 1619566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of beta-methyldigoxin in healthy humans II: Oral studies and bioavailability.
    Hinderling PH; Garrett ER; Wester RC
    J Pharm Sci; 1977 Mar; 66(3):314-25. PubMed ID: 845795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excretion of hydroflumethiazide in bile and urine of man.
    Brørs O; Haffner JF; Jacobsen S
    Eur J Clin Pharmacol; 1979 May; 15(4):287-9. PubMed ID: 477714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meperidine disposition in man: influence of urinary pH and route of administration.
    Verbeeck RK; Branch RA; Wilkinson GR
    Clin Pharmacol Ther; 1981 Nov; 30(5):619-28. PubMed ID: 7297021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
    Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of a single oral dose of hydroflumethiazide in health and in cardiac failure.-.
    Brørs O; Jacobsen S; Arnesen E
    Eur J Clin Pharmacol; 1978 Nov; 14(1):29-37. PubMed ID: 729604
    [No Abstract]   [Full Text] [Related]  

  • 20. Bioavailability and kinetics of maprotiline.
    Alkalay D; Wagner WE; Carlsen S; Khemani L; Volk J; Bartlett MF; LeSher A
    Clin Pharmacol Ther; 1980 May; 27(5):697-703. PubMed ID: 7371367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.